Effects of rosmarinic acid on an experimental model of painful diabetic neuropathy in rats

Pharmaceutical Biology

Volumn 52, Issue 11, 2014, Pages 1398-1402

  Hasanein, Parisa ^a   Mohammad Zaheri, Leila ^a  

^a BU ALI SINA UNIVERSITY   (Iran)

Author keywords

Allodynia; Diabetes; Hyperalgesia; Hyperglycemia; Nociception; Rats

Indexed keywords

ROSMARINIC ACID; CINNAMIC ACID DERIVATIVE; DEPSIDE; GLUCOSE BLOOD LEVEL; NONSTEROID ANTIINFLAMMATORY AGENT;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BLOOD ANALYSIS; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FORMALIN TEST; GLUCOSE BLOOD LEVEL; LATENT PERIOD; LOW DRUG DOSE; MALE; NONHUMAN; RAT; TAIL FLICK TEST; WEIGHT CHANGE; ANIMAL; BLOOD; DIABETIC NEUROPATHIES; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PAIN; PAIN MEASUREMENT; PROCEDURES; TREATMENT OUTCOME; WISTAR RAT;

RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; CINNAMATES; DEPSIDES; DIABETIC NEUROPATHIES; DISEASE MODELS, ANIMAL; MALE; PAIN; PAIN MEASUREMENT; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 84912135495     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2014.894090     Document Type: Article

References (31)

1. Calcutt NA, Jorge MC, Yaksh TL, Chaplan SR. (1996). Tactile allodynia and formalin hyperalgesia in streptozotocin-diabetic rats: Effects of insulin, aldose reductase inhibition and lidocaine. Pain 68:293-9.
2. Calcutt NA. (2002). Potential mechanisms of neuropathic pain states. Int Rev Neurobiol 50:205-28.
3. Calcutt NA. (2004). Experimental models of painful diabetic neuropathy. J Neurol Sci 220:137-9.
4. Calcutt NA, Freshwater JD, Mizisin AP. (2004). Prevention of sensory disorders in diabetic Sprague-Dawley rats by aldose reductase inhibition or treatment with ciliary neurotrophic factor. Diabetologia 47:718-24.
5. Can OD, Oztürk Y, Oztürk N, et al. (2011). Effects of treatment with St. John's Wort on blood glucose levels and pain perceptions of streptozotocin-diabetic rats. Fitoterapia 82:576-84.
6. Chaplan SR, Bach FW, Pogrel JW, et al. (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63.
7. Chu X, Ci X, He J, et al. (2012). Effects of a natural prolyl oligopeptidase inhibitor, rosmarinic acid, on lipopolysaccharide-induced acute lung injury in mice. Molecules 17:3586-98.
8. Courteix C, Eschalier A, Lavarenne J. (1993). Streptozotocin-induced diabetic rats: Behavioral evidence for a model of chronic pain. Pain 53:81-8.
9. Craig WJ. (1999). Health-promoting properties of common herbs. Am J Clin Nutr 70:S491-9.
10. Freshwater JD, Malmberg AB, Calcutt NA. (2002). Elevated spinal cyclooxygenase and prostaglandin release during hyperalgesia in diabetic rats. Diabetes 51:2249-55.
11. Guginski G, Luiz AP, Silva MD, et al. (2009). Mechanisms involved in the antinociception caused by ethanolic extract obtained from the leaves of Melissa officinalis (lemon balm) in mice. Pharmacol Biochem Behav 93:6-10.
12. Gupta M, Singh J, Sood S, Arora B. (2003). Mechanism of antinociceptive effect of nimodipine in experimental diabetic neuropathic pain. Methods Find Exp Clin Pharmacol 25:49-52.
13. Gutierrez T, Nackley AG, Neely MH, et al. (2003). Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. Brain Res 987:85-176.
14. Hasanein P, Parviz M, Keshavarz M, et al. (2006). Oral magnesium administration prevents thermal hyperalgesia induced by diabetes in rats. Diabetes Res Clin Pract 73:17-22.
15. Hasanein P, Parviz M, Keshavarz M, Roohbakhsh A. (2009). URB597, an inhibitor of fatty acid amide hydrolase, reduces hyperalgesia in diabetic rats. Can J Physiol Pharmacol 87:432-9.
16. Hasanein P, Soltani N. (2009). Effects of the endocannabinoid transport inhibitors AM404 and UCM707 on diabetic neuropathy in rats. Clin Exp Pharmacol Physiol 36:1127-31.
17. Jiang WL, Xu Y, Zhang SP, et al. (2012). Effect of rosmarinic acid on experimental diabetic nephropathy. Basic Clin Pharmacol Toxicol 10: 390-5.
18. Jolivalt CG, Lee CA, Ramos KM, Calcutt NA. (2008). Allodynia and hyperalgesia in diabetic rats are mediated by GABA and depletion of spinal potassium-chloride co-transporters. Pain 15:48-57.
19. Lee JH, McCarty R. (1992). Pain threshold in diabetic rats: Effects of good versus poor diabetic control. Pain 50:231-6.
20. Luan H, Kan Z, Xu Y, et al. (2013). Rosmarinic acid protects against experimental diabetes with cerebral ischemia: Relation to inflammation response. J Neuroinflammation 17:10-28.
21. Lucarini R, Bernardes WA, Ferreira DS, et al. (2013). In vivo analgesic and anti-inflammatory activities of Rosmarinus officinalis aqueous extracts, rosmarinic acid and its acetyl ester derivative. Pharm Biol 51:1087-90.
22. Malcangio M, Tomlinson DR. (1998). A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain 76: 151-7.
23. Moon DO, Kim MO, Lee JD, et al. (2010). Rosmarinic acid sensitizes cell death through suppression of TNF-A-induced NF-kB activation and ROS generation in human leukemia U937 cells. Cancer Lett 288: 183-191.
24. Murakami T, Iwanaga T, Ogawa Y, et al. (2013). Development of sensory neuropathy in streptozotocin-induced diabetic mice. Brain Behav 3:35-41.
25. Obrosova IG. (2003). Update on the pathogenesis of diabetic neuropathy. Curr Diab Rep 3:439-45.
26. O'Connor AB, Dworkin RH. (2009). Treatment of neuropathic pain: An overview of recent guidelines. Am J Med 122:S22-32.
27. Ono K, Li L, Takamura Y, et al. (2012). Phenolic compounds prevent amyloid b-protein oligomerization and synaptic dysfunction by site-specific binding. J Biol Chem 287:14631-43.
28. Shetty K. (2005). Rosmarinic acid biosynthesis and mechanism of action. In: Shetty K, Paliyath G, Pometto AL, III, Levin RE, eds. Food Biotechnology, 2nd ed. Boca Raton: CRC Press, 825-45.
29. Sotnikova R, Okruhlicova L, Vlkovicova J, et al. (2013). Rosmarinic acid administration attenuates diabetes-induced vascular dysfunction of the rat aorta. J Pharm Pharmacol 65:713-23.
30. Tjølsen A, Berge OG, Hunskaar S, et al. (1992). The formalin test: An evaluation of the method. Pain 51:5-17.
31. Yagihashi S. (1995). Pathology and pathogenetic mechanisms of diabetic neuropathy. Diab Metab Rev 11:193-225.